---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-005702"
form_type: "8-K"
ticker: "PPCB"
cik: "0001517681"
company_name: "Propanc Biopharma, Inc."
filed_at: "2023-02-21T23:59:59+00:00"
generated_at: "2026-06-19T06:51:49.820485+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Propanc Biopharma issues $111,111 convertible note to ONE44 Capital LLC

## Summary
- Principal $111,111; net proceeds $100,000 after $11,111 original issue discount.
- Interest 10% per annum, payable in common stock; maturity Feb 14, 2024.
- Conversion price at 60% of lowest trading price over prior 10 days (50% if DTC chill).
- Prepayment allowed within 180 days with premiums of 120%-135% of face amount.
- Proceeds used for general working capital; note issued under Section 4(a)(2) exemption.

## SEC filing metadata
- accession: 0001493152-23-005702
- form_type: 8-K
- ticker: PPCB
- cik: 0001517681
- company_name: Propanc Biopharma, Inc.
- filed_at: 2023-02-21T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517681/000149315223005702/0001493152-23-005702-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517681/000149315223005702/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-005702
- JSON: https://secwatch.observer/filing/0001493152-23-005702.json
- Plain text: https://secwatch.observer/filing/0001493152-23-005702.txt

## Key facts
- Debt Financings
  Propanc Biopharma, Inc. incurred convertible notes of aggregate principal amount of $111,111 with ONE44 Capital LLC at 10% per annum maturing February 14, 2024.
  - Instrument: convertible notes
  - Principal: aggregate principal amount of $111,111
  - Counterparty: ONE44 Capital LLC
  - Rate: 10% per annum
  - Maturity: February 14, 2024
  - Event: incurrence
  source text: On February 14, 2023, Propanc Biopharma, Inc. (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with ONE44 Capital LLC (“ONE44”), pursuant to which ONE44 purchased a convertible promissory note (the “Note”) from the Company in the aggregate principal amount of $111,111, such principal and the interest thereon convertible into shares of the Company’s common stock at the option of ONE44.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517681/000149315223005702/0001493152-23-005702-index.htm
- Material Agreements
  Propanc Biopharma, Inc. entered into Purchase Agreement with ONE44 Capital LLC valued at aggregate principal amount of $111,111 (effective 2023-02-14).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: ONE44 Capital LLC
  - Value: aggregate principal amount of $111,111
  - Effective: 2023-02-14
  source text: On February 14, 2023, Propanc Biopharma, Inc. (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with ONE44 Capital LLC (“ONE44”), pursuant to which ONE44 purchased a convertible promissory note (the “Note”) from the Company in the aggregate principal amount of $111,111
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517681/000149315223005702/0001493152-23-005702-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.